Akiko Emi
Hiroshima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.
Journal: Clinical breast cancer
Published: February 10, 2026
Development and validation of a nomogram incorporating YpT stage for predicting ypN0 using multicenter data in clinically node-positive breast cancer.
Journal: Scientific reports
Published: June 04, 2025
Diagnostic performance of TILs-US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer.
Journal: International journal of clinical oncology
Published: June 14, 2024
A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score.
Journal: Japanese journal of clinical oncology
Published: April 01, 2024
A Case of Breast Metastasis from Renal Cell Carcinoma
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: February 03, 2023
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.
Journal: Anticancer research
Published: October 30, 2022
Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
Journal: Anticancer research
Published: August 30, 2022
Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
Journal: Breast cancer (Tokyo, Japan)
Published: July 21, 2022
Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: June 13, 2022
The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
Journal: Journal of medical ultrasonics (2001)
Published: May 02, 2022
The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.
Journal: Surgical oncology
Published: October 10, 2021
Last Updated: 09/26/2026